{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:58Z","timestamp":1792788238145,"version":"4.5.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary antibody deficiency (SAD) represents a substantial yet under-recognised global healthcare burden. It is more prevalent than primary antibody deficiency, but frequently under-diagnosed and variably managed worldwide. Prompt diagnosis is often hindered by insufficient awareness among clinicians, lack of global consensus on screening\/monitoring for SAD among at-risk patients, inadequate clinical immunology services and lack of standardised referral pathways\/protocols. Management practices vary widely, with little international agreement, particularly regarding threshold to initiate immunoglobulin replacement, as well as regimen, dosage and frequency of immunoglobulin administration. Subcutaneous immunoglobulin (SCIg) replacement emerged as a promising alternative to traditional intravenous immunoglobulin (IVIg) replacement. IVIg requires monthly infusions in inpatient\/day-hospital settings leading to high peak serum IgG and subsequent variations with end-of-cycle \u2018wear-off effect\u2019, causing more systemic side effects and increased risk of breakthrough infections, and disruption of daily life and employment. While previous evidence was largely derived from primary antibody deficiency, recent comparative studies on SAD patients indicate that SCIg replacement, through weekly self-administered infusions, can achieve more stable and higher trough serum IgG, lower infection rates, fewer systemic adverse reactions and enhanced health-related quality-of-life compared to IVIg. There is also potential cost-savings from the use of SCIg replacement. This review emphasises the urgent need for standardised guidelines on screening\/diagnosis and treatment of SAD, and large-scale multi-centre trials and real-world studies on IVIg vs SCIg replacement among SAD patients, which will facilitate better identification, management, and health-outcomes for SAD patients, ultimately alleviating a significant global health challenge through coordinated clinical, research, and policy efforts.<\/jats:p>","DOI":"10.1007\/s12016-025-09116-4","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T10:53:43Z","timestamp":1765018423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bridging the Gap in Secondary Antibody Deficiencies: Current Evidence and Unmet Needs in Diagnosis and Management with Immunoglobulin Replacement"],"prefix":"10.1007","volume":"68","author":[{"given":"Andy Ka Chun","family":"Kan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Chun Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chak Sing","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"9116_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984110","volume":"13","author":"AKC Kan","year":"2022","unstructured":"Kan AKC, Leung GMK, Chiang V, Au EYL, Lau CS, Li PH (2022) Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese. Front Immunol 13:984110. https:\/\/doi.org\/10.3389\/fimmu.2022.984110","journal-title":"Front Immunol"},{"issue":"7","key":"9116_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3346\/jkms.2012.27.7.788","volume":"27","author":"JW Rhim","year":"2012","unstructured":"Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, Kim HM, Park HJ, Pai KS, Son BK, Shin KS, Oh MY, Woo YJ, Yoo Y, Lee KS, Lee KY, Lee CG, Lee JS, Chung EH, Choi EH, Hahn YS, Park HY, Kim JG (2012) Prevalence of primary immunodeficiency in Korea. J Korean Med Sci 27(7):788\u2013793. https:\/\/doi.org\/10.3346\/jkms.2012.27.7.788","journal-title":"J Korean Med Sci"},{"issue":"Suppl 1","key":"9116_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2249.2009.03954.x","volume":"157","author":"B Gathmann","year":"2009","unstructured":"Gathmann B, Grimbacher B, Beaut\u00e9 J, Dudoit Y, Mahlaoui N, Fischer A, Knerr V, Kindle G (2009) The European internet-based patient and research database for primary immunodeficiencies: results 2006\u20132008. Clin Exp Immunol 157(Suppl 1):3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03954.x","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"9116_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.iac.2015.07.001","volume":"35","author":"N Raje","year":"2015","unstructured":"Raje N, Dinakar C (2015) Overview of immunodeficiency disorders. Immunol Allergy Clin North Am 35(4):599\u2013623. https:\/\/doi.org\/10.1016\/j.iac.2015.07.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"9116_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S (2019) The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol 10:33. https:\/\/doi.org\/10.3389\/fimmu.2019.00033","journal-title":"Front Immunol"},{"issue":"6","key":"9116_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","volume":"16","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Wood P (2016) Secondary antibody deficiency - causes and approach to diagnosis. Clin Med Lond 16(6):571\u2013576. https:\/\/doi.org\/10.7861\/clinmedicine.16-6-571","journal-title":"Clin Med Lond"},{"issue":"1","key":"9116_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/hkbrd-2017-0001","volume":"17","author":"PH Li","year":"2017","unstructured":"Li PH, Lau CS (2017) Secondary antibody deficiency and immunoglobulin replacement. Hong Kong Bull Rheum 17(1):1\u20135. https:\/\/doi.org\/10.1515\/hkbrd-2017-0001","journal-title":"Hong Kong Bull Rheum"},{"issue":"Suppl 3","key":"9116_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-024-00925-4","volume":"20","author":"P Pourshahnazari","year":"2025","unstructured":"Pourshahnazari P, Betschel SD, Kim VHD, Waserman S, Zhu R, Kim H (2025) Secondary immunodeficiency. Allergy Asthma Clin Immunol 20(Suppl 3):80. https:\/\/doi.org\/10.1186\/s13223-024-00925-4","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"9116_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100506","volume":"4","author":"AKC Kan","year":"2025","unstructured":"Kan AKC, Chiang V, Au EYL, Lau CS, Li PH (2025) Disparities in health-related quality of life between patients with primary and secondary antibody deficiencies. Journal of Allergy and Clinical Immunology: Global 4(3):100506. https:\/\/doi.org\/10.1016\/j.jacig.2025.100506","journal-title":"Journal of Allergy and Clinical Immunology: Global"},{"issue":"3","key":"9116_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2249.2007.03432.x","volume":"149","author":"P Wood","year":"2007","unstructured":"Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, Hyde C, Chapel H (2007) Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 149(3):410\u2013423. https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03432.x","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"9116_CR11","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1002\/ajh.25681","volume":"95","author":"M Mattsson","year":"2020","unstructured":"Mattsson M, Sandin F, Kimby E, H\u00f6glund M, Glimelius I (2020) Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: a nationwide population-based study. Am J Hematol 95(2):E36\u2013e38. https:\/\/doi.org\/10.1002\/ajh.25681","journal-title":"Am J Hematol"},{"issue":"4","key":"9116_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3816\/CLML.2010.n.061","volume":"10","author":"A Panovsk\u00e1","year":"2010","unstructured":"Panovsk\u00e1 A, Doubek M, Brychtov\u00e1 Y, Mayer J (2010) Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech leukemia study group for life (CELL). Clin Lymphoma Myeloma Leuk 10(4):297\u2013300. https:\/\/doi.org\/10.3816\/CLML.2010.n.061","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10159","key":"9116_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/s0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 392(10159):1789\u20131858. https:\/\/doi.org\/10.1016\/s0140-6736(18)32279-7","journal-title":"Lancet"},{"issue":"2","key":"9116_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jha2.95","volume":"1","author":"N Singh","year":"2020","unstructured":"Singh N, Mott SL, Sutamtewagul G, McCarthy A, Slager SL, Cerhan JR, Ballas Z, Link BK (2020) Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem 1(2):537\u2013544. https:\/\/doi.org\/10.1002\/jha2.95","journal-title":"EJHaem"},{"issue":"1","key":"9116_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83630-x","volume":"15","author":"Q Hou","year":"2025","unstructured":"Hou Q, Li X, Ma H, Fu D, Liao A (2025) A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. Sci Rep 15(1):2204. https:\/\/doi.org\/10.1038\/s41598-024-83630-x","journal-title":"Sci Rep"},{"issue":"13","key":"9116_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362\u20131369. https:\/\/doi.org\/10.1056\/NEJMoa054494","journal-title":"N Engl J Med"},{"issue":"25","key":"9116_CR17","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582\u20132590. https:\/\/doi.org\/10.1056\/NEJMoa070389","journal-title":"N Engl J Med"},{"issue":"12","key":"9116_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188988","volume":"12","author":"R S\u00f8rrig","year":"2017","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted AJ, Fr\u00f8lund UC, Andersen KT, Klostergaard A, Helleberg C, Pedersen RS, Pedersen PT, Helm-Petersen S, Teodorescu EM, Preiss B, Abildgaard N, Gimsing P (2017) Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population. PLoS One 12(12):e0188988. https:\/\/doi.org\/10.1371\/journal.pone.0188988","journal-title":"PLoS One"},{"key":"9116_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1334899","volume":"15","author":"D Brazel","year":"2024","unstructured":"Brazel D, Grant C, Cabal A, Chen WP, Pinter-Brown L (2024) Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis. Front Immunol 15:1334899. https:\/\/doi.org\/10.3389\/fimmu.2024.1334899","journal-title":"Front Immunol"},{"issue":"1","key":"9116_CR20","doi-asserted-by":"publisher","first-page":"e70014","DOI":"10.1002\/hon.70014","volume":"43","author":"\u00c5 Lindberg","year":"2025","unstructured":"Lindberg \u00c5, Johansson \u00c5, Kahn F, J\u00f6nsson G, Jerkeman M (2025) Hypogammaglobulinemia at diagnosis is associated with inferior survival and higher risk of infections in diffuse large B cell lymphoma. Hematol Oncol 43(1):e70014. https:\/\/doi.org\/10.1002\/hon.70014","journal-title":"Hematol Oncol"},{"issue":"4","key":"9116_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","volume":"75","author":"M Hocao\u01e7lu","year":"2023","unstructured":"Hocao\u01e7lu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, Giblon RE, Zand L, Fervenza FC, Helmick CG, Crowson CS, Duarte-Garc\u00eda A (2023) Incidence, Prevalence, and mortality of lupus nephritis: A Population-Based study over four decades using the lupus Midwest network. Arthritis Rheumatol 75(4):567\u2013573. https:\/\/doi.org\/10.1002\/art.42375","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9116_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000229","volume":"4","author":"DE Smilek","year":"2017","unstructured":"Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D (2017) Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Sci Med 4(1):e000229. https:\/\/doi.org\/10.1136\/lupus-2017-000229","journal-title":"Lupus Sci Med"},{"key":"9116_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2018.12.003","volume":"208","author":"Z Ye","year":"2019","unstructured":"Ye Z, Huang Y, Wang Y, Lu J, Wu J, Yu Z (2019) Phenotype and genotype of a cohort of Chinese children with early-onset protein-losing enteropathy. J Pediatr 208:38\u201342e3. https:\/\/doi.org\/10.1016\/j.jpeds.2018.12.003","journal-title":"J Pediatr"},{"issue":"6","key":"9116_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/clinpract13060115","volume":"13","author":"MS Alhamadh","year":"2023","unstructured":"Alhamadh MS, Alhowaish TS, Mathkour A, Altamimi B, Alheijani S, Alrashid A (2023) Infection risk, mortality, and hypogammaglobulinemia prevalence and associated factors in adults treated with rituximab: a tertiary care center experience. Clin Pract 13(6):1286\u20131302. https:\/\/doi.org\/10.3390\/clinpract13060115","journal-title":"Clin Pract"},{"issue":"7","key":"9116_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"key":"9116_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009","journal-title":"J Autoimmun"},{"issue":"12","key":"9116_CR27","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","volume":"39","author":"F De Angelis","year":"2015","unstructured":"De Angelis F, Tosti ME, Capria S, Russo E, D\u2019Elia GM, Annechini G, Stefanizzi C, Fo\u00e0 R, Pulsoni A (2015) Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res 39(12):1382\u20131388. https:\/\/doi.org\/10.1016\/j.leukres.2015.10.013","journal-title":"Leuk Res"},{"issue":"4","key":"9116_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","volume":"36","author":"C Wirsum","year":"2016","unstructured":"Wirsum C, Glaser C, Gutenberger S, Keller B, Unger S, Voll RE, Vach W, Ness T, Warnatz K (2016) Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol 36(4):406\u2013412. https:\/\/doi.org\/10.1007\/s10875-016-0264-7","journal-title":"J Clin Immunol"},{"issue":"7","key":"9116_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0961203314525248","volume":"23","author":"DY Yap","year":"2014","unstructured":"Yap DY, Yung S, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM (2014) Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Lupus 23(7):678\u2013683. https:\/\/doi.org\/10.1177\/0961203314525248","journal-title":"Lupus"},{"issue":"12","key":"9116_CR30","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s00277-021-04649-y","volume":"100","author":"E Karakulska-Prystupiuk","year":"2021","unstructured":"Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J, Drozd-Soko\u0142owska J, Kmin E, Chlebus M, Szczypi\u0144ska K, Boguradzki P, Tomaszewska A, M\u0105dry K, Bili\u0144ski J, Basak GW, J\u0119drzejczak WW (2021) Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis. Ann Hematol 100(12):3007\u20133016. https:\/\/doi.org\/10.1007\/s00277-021-04649-y","journal-title":"Ann Hematol"},{"issue":"10","key":"9116_CR31","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","volume":"13","author":"DF Florescu","year":"2013","unstructured":"Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U (2013) What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 13(10):2601\u20132610. https:\/\/doi.org\/10.1111\/ajt.12401","journal-title":"Am J Transplant"},{"issue":"5","key":"9116_CR32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, Engel E, Walter JE, Truong TQ, Khan DA, Ballow M, Cunningham-Rundles C, Lu H, Kwan M, Barmettler S (2022) Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol 149(5):1525\u20131560. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9116_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/aci.0000000000000222","volume":"15","author":"S Holding","year":"2015","unstructured":"Holding S, Jolles S (2015) Current screening approaches for antibody deficiency. Curr Opin Allergy Clin Immunol 15(6):547\u2013555. https:\/\/doi.org\/10.1097\/aci.0000000000000222","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"9116_CR34","doi-asserted-by":"publisher","unstructured":"Wonnaparhown A, Hilal T, Chong A, Fonseca R (2025) Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions. Blood Rev 101316. https:\/\/doi.org\/10.1016\/j.blre.2025.101316","DOI":"10.1016\/j.blre.2025.101316"},{"issue":"6","key":"9116_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100324","volume":"9","author":"SS Duraisingham","year":"2014","unstructured":"Duraisingham S, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst J (2014) Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One 9(6):e100324. https:\/\/doi.org\/10.1371\/journal.pone.0100324","journal-title":"PLoS One"},{"issue":"6","key":"9116_CR36","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10875-022-01274-w","volume":"42","author":"P Ryan","year":"2022","unstructured":"Ryan P, Redenbaugh V, McGucken J, Kindle G, Devlin LA, Coulter T, Buckland MS, Sepp\u00e4nen MRJ, Conlon NP, Feighery C, Edgar JDM (2022) Inborn errors of immunity on the island of Ireland - a cross-jurisdictional UKPID\/ESID registry report. J Clin Immunol 42(6):1293\u20131299. https:\/\/doi.org\/10.1007\/s10875-022-01274-w","journal-title":"J Clin Immunol"},{"key":"9116_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00586","volume":"10","author":"S S\u00e1nchez-Ram\u00f3n","year":"2019","unstructured":"S\u00e1nchez-Ram\u00f3n S, Berm\u00fadez A, Gonz\u00e1lez-Granado LI, Rodr\u00edguez-Gallego C, Sastre A, Soler-Palac\u00edn P (2019) Primary and secondary immunodeficiency diseases in oncohaematology: warning signs, diagnosis, and management. Front Immunol 10:586. https:\/\/doi.org\/10.3389\/fimmu.2019.00586","journal-title":"Front Immunol"},{"issue":"1","key":"9116_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000337","volume":"6","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne D, Mukhtyar C, Karim MY (2019) Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. Lupus Sci Med 6(1):e000337. https:\/\/doi.org\/10.1136\/lupus-2019-000337","journal-title":"Lupus Sci Med"},{"issue":"1","key":"9116_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01107-6","volume":"14","author":"A Wonnaparhown","year":"2024","unstructured":"Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R (2024) IgG replacement in multiple myeloma. Blood Cancer J 14(1):124. https:\/\/doi.org\/10.1038\/s41408-024-01107-6","journal-title":"Blood Cancer J"},{"issue":"1","key":"9116_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U (2021) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019","journal-title":"Ann Oncol"},{"issue":"5","key":"9116_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bjh.18075","volume":"197","author":"R Walewska","year":"2022","unstructured":"Walewska R, Parry-Jones N, Eyre TA, Follows G, Martinez-Calle N, McCarthy H, Parry H, Patten PEM, Riches JC, Hillmen P, Schuh AH (2022) Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol 197(5):544\u2013557. https:\/\/doi.org\/10.1111\/bjh.18075","journal-title":"Br J Haematol"},{"issue":"3","key":"9116_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","volume":"22","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M (2024) Chronic lymphocytic Leukemia\/Small lymphocytic Lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(3):175\u2013204. https:\/\/doi.org\/10.6004\/jnccn.2024.0018","journal-title":"J Natl Compr Canc Netw"},{"issue":"25","key":"9116_CR43","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O\u2019Brien S, Robak T, Seymour JF, Kipps TJ (2018) IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"9116_CR44","unstructured":"National Institute for Health and Care Excellence (2016) Myeloma: diagnosis and management.\u00a0https:\/\/www.nice.org.uk\/guidance\/ng35\/chapter\/Recommendations#preventing-and-managing-complications. Accessed 21 Apr 2024."},{"issue":"12","key":"9116_CR45","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","volume":"50","author":"M Bukhari","year":"2011","unstructured":"Bukhari M, Abernethy R, Deighton C, Ding T, Hyrich K, Lunt M, Luqmani R, Kiely P, Bosworth A, Ledingham J, Ost\u00f6r A, Gadsby K, McKenna F, Finney D, Dixey J (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50(12):2311\u20132313. https:\/\/doi.org\/10.1093\/rheumatology\/ker106a","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9116_CR46","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, Chan C, Yusuf MA, Litwic A, Smolen S, Topliffe J, Bennett S, Humphreys J, Green M, Ledingham J (2019) The British society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford) 58(2):e3\u2013e42. https:\/\/doi.org\/10.1093\/rheumatology\/key208","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"9116_CR47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","volume":"57","author":"C Gordon","year":"2018","unstructured":"Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D\u2019Cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D (2018) The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 57(1):e1\u2013e45. https:\/\/doi.org\/10.1093\/rheumatology\/kex286","journal-title":"Rheumatology (Oxford)"},{"key":"9116_CR48","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","DOI":"10.1136\/ard-2022-223356"},{"issue":"7","key":"9116_CR49","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Mill\u00e1n I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res Hoboken 73(7):924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res Hoboken"},{"issue":"1","key":"9116_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Mahr A, Merkel PA, Mohammad AJ, Monti S, Mukhtyar CB, Musial J, Price-Kuehne F, Segelmark M, Teng YKO, Terrier B, Tomasson G, Vaglio A, Vassilopoulos D, Verhoeven P, Jayne D (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83(1):30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9116_CR51","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA (2021) 2021 American college of Rheumatology\/Vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73(8):1366\u20131383. https:\/\/doi.org\/10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"9116_CR52","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.bbmt.2018.01.017","volume":"24","author":"S Bhella","year":"2018","unstructured":"Bhella S, Majhail S, Betcher J, Costa J, Daly A, Dandoy E, DeFilipp Z, Doan V, Gulbis A, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah N, Stricherz M, Viswabandya A, Bredeson C, Seftel D (2018) Choosing wisely BMT: American society for blood and marrow transplantation and Canadian blood and marrow transplant group\u2019s list of 5 tests and treatments to question in blood and marrow transplantation. Biol Blood Marrow Transpl 24(5):909\u2013913. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"9116_CR53","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl 15(10):1143\u20131238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","journal-title":"Biol Blood Marrow Transpl"},{"key":"9116_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13601-019-0245-z","volume":"9","author":"N Fyhrquist","year":"2019","unstructured":"Fyhrquist N, Werfel T, Bil\u00f2 MB, M\u00fclleneisen N, van Gerth R (2019) The roadmap for the allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper. Clin Transl Allergy 9:3. https:\/\/doi.org\/10.1186\/s13601-019-0245-z","journal-title":"Clin Transl Allergy"},{"issue":"8","key":"9116_CR55","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1016\/j.jaip.2020.04.018","volume":"8","author":"D Sun","year":"2020","unstructured":"Sun D, Heimall J (2020) Geographical distribution of allergy\/immunology providers in the United States and association with median income. J Allergy Clin Immunol Pract 8(8):2802\u20132804e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.04.018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"9116_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/ap-250817-0150","volume":"37","author":"TH Lee","year":"2019","unstructured":"Lee TH, Leung TF, Wong G, Ho M, Duque JR, Li PH, Lau CS, Lam WF, Wu A, Chan E, Lai C, Lau YL (2019) The unmet provision of allergy services in Hong Kong impairs capability for allergy prevention-implications for the Asia Pacific region. Asian Pac J Allergy Immunol 37(1):1\u20138. https:\/\/doi.org\/10.12932\/ap-250817-0150","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"2","key":"9116_CR57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000090502","volume":"139","author":"JO Warner","year":"2006","unstructured":"Warner JO, Kaliner MA, Crisci CD, Del Giacco S, Frew AJ, Liu GH, Maspero J, Moon HB, Nakagawa T, Potter PC, Rosenwasser LJ, Singh AB, Valovirta E, Van Cauwenberge P (2006) Allergy practice worldwide: a report by the World Allergy Organization specialty and training council. Int Arch Allergy Immunol 139(2):166\u2013174. https:\/\/doi.org\/10.1159\/000090502","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"9116_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13223","volume":"102","author":"IK Na","year":"2019","unstructured":"Na IK, Buckland M, Agostini C, Edgar JDM, Friman V, Michallet M, S\u00e1nchez-Ram\u00f3n S, Scheibenbogen C, Quinti I (2019) Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol 102(6):447\u2013456. https:\/\/doi.org\/10.1111\/ejh.13223","journal-title":"Eur J Haematol"},{"issue":"3","key":"9116_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J (2017) When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol 188(3):333\u2013341. https:\/\/doi.org\/10.1111\/cei.12915","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"9116_CR60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ejh.13580","volume":"106","author":"S Jolles","year":"2021","unstructured":"Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, Trentin L, L\u00e9vy V (2021) Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol 106(4):439\u2013449. https:\/\/doi.org\/10.1111\/ejh.13580","journal-title":"Eur J Haematol"},{"issue":"3","key":"9116_CR61","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jaip.2024.12.024","volume":"13","author":"IM Otani","year":"2025","unstructured":"Otani IM, Ballow M (2025) If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia. J Allergy Clin Immunol Pract 13(3):511\u2013521. https:\/\/doi.org\/10.1016\/j.jaip.2024.12.024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"9116_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cei\/uxac070","volume":"210","author":"S Grigoriadou","year":"2022","unstructured":"Grigoriadou S, Clubbe R, Garcez T, Huissoon A, Grosse-Kreul D, Jolles S, Henderson K, Edmonds J, Lowe D, Bethune C (2022) British society for immunology and united Kingdom primary immunodeficiency network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy. Clin Exp Immunol 210(1):1\u201313. https:\/\/doi.org\/10.1093\/cei\/uxac070","journal-title":"Clin Exp Immunol"},{"key":"9116_CR63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","volume":"52","author":"A Pecoraro","year":"2017","unstructured":"Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G (2017) Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach. Int Immunopharmacol 52:136\u2013142. https:\/\/doi.org\/10.1016\/j.intimp.2017.09.005","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"9116_CR64","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"issue":"3","key":"9116_CR65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, H\u00e1jek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol 32(3):309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"9116_CR66","doi-asserted-by":"publisher","unstructured":"Lichvar AB, Ensor CR, Zeevi A, Morrell MR, Pilewski JM, Hayanga JWA, D\u2019Cunha J, McDyer JF, Petrov AA (2018) Detrimental association of hypogammaglobulinemia with chronic lung allograft dysfunction and death is not mitigated by on-demand immunoglobulin G replacement after lung transplantation. Prog Transplant. https:\/\/doi.org\/10.1177\/1526924818817028","DOI":"10.1177\/1526924818817028"},{"issue":"8","key":"9116_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000000811","volume":"4","author":"AA Petrov","year":"2018","unstructured":"Petrov AA, Traister RS, Crespo MM, Silveira FP, Xie M, Coffey K, Ensor CR, Landsittel D, Pilewski JM (2018) A prospective observational study of hypogammaglobulinemia in the first year after lung transplantation. Transpl Direct 4(8):e372. https:\/\/doi.org\/10.1097\/txd.0000000000000811","journal-title":"Transpl Direct"},{"issue":"2","key":"9116_CR68","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.transproceed.2015.12.064","volume":"48","author":"JA Poole","year":"2016","unstructured":"Poole JA, Qiu F, Kalil AC, Grant W, Mercer DF, Florescu DF (2016) Impact of immunoglobulin therapy in intestinal transplant recipients with posttransplantation hypogammaglobulinemia. Transplant Proc 48(2):479\u201384. https:\/\/doi.org\/10.1016\/j.transproceed.2015.12.064","journal-title":"Transplant Proc"},{"issue":"3","key":"9116_CR69","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1200\/op.20.00312","volume":"17","author":"BA Derman","year":"2021","unstructured":"Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW (2021) Changes in intravenous immunoglobulin usage for hypogammaglobulinemia after implementation of a stewardship program. JCO Oncol Pract 17(3):e445\u2013e453. https:\/\/doi.org\/10.1200\/op.20.00312","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"9116_CR70","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/1744666x.2020.1788939","volume":"16","author":"V Patel","year":"2020","unstructured":"Patel V, Cowan J (2020) Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Rev Clin Immunol 16(7):711\u2013716. https:\/\/doi.org\/10.1080\/1744666x.2020.1788939","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"9116_CR71","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2900","volume":"39","author":"V Patel","year":"2021","unstructured":"Patel V, Cameron DW, Cowan J (2021) Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy. Hematol Oncol 39(4):584\u2013588. https:\/\/doi.org\/10.1002\/hon.2900","journal-title":"Hematol Oncol"},{"key":"9116_CR72","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood-2023-181541","volume":"142","author":"MW Erica","year":"2023","unstructured":"Erica MW, Khai Li C, John R, Jennifer G, Brendan B, Jeannie C, Kyle RC, Philip JC, Laura F, Michael G, Andrew PG, Eliza AH, Morrissey CO, Stephen PM, Stephen SO, David LP, Dennis P, Jason AR, Elizabeth GR, Andrew S, Simon JS, Le Thi Phuong T, Judith T, Neil AW, Robert W, Zoe KM (2023) Optimizing Immunoglobulin replacement therapy for patients with B-Cell malignancies and hypogammaglobulinemia: the Investigator-Initiated, International, randomized phase II\/III rational platform Trial, and the rationalise (STOP IgRT) domain. Blood 142:1295. https:\/\/doi.org\/10.1182\/blood-2023-181541","journal-title":"Blood"},{"issue":"7","key":"9116_CR73","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/bloodadvances.2023011231","volume":"8","author":"ZK McQuilten","year":"2024","unstructured":"McQuilten ZK, Weinkove R, Thao LTP, Crispin P, Degelia A, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey CO, Wood EM (2024) Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. Blood Adv 8(7):1787\u20131795. https:\/\/doi.org\/10.1182\/bloodadvances.2023011231","journal-title":"Blood Adv"},{"issue":"3 Suppl","key":"9116_CR74","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","volume":"130","author":"JS Orange","year":"2012","unstructured":"Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of Allergy, asthma & immunology. J Allergy Clin Immunol 130(3 Suppl):S1\u201324. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.002","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9116_CR75","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.anai.2019.08.012","volume":"123","author":"RA Marsh","year":"2019","unstructured":"Marsh RA, Orange JS (2019) Antibody deficiency testing for primary immunodeficiency: A practical review for the clinician. Ann Allergy Asthma Immunol 123(5):444\u2013453. https:\/\/doi.org\/10.1016\/j.anai.2019.08.012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"9116_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1203475418811335","volume":"23","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J (2019) Vaccination guidelines for patients with Immune-Mediated disorders on immunosuppressive therapies. J Cutan Med Surg 23(1):50\u201374. https:\/\/doi.org\/10.1177\/1203475418811335","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"9116_CR77","doi-asserted-by":"publisher","first-page":"366e1","DOI":"10.1016\/j.jtct.2022.04.017","volume":"28","author":"A Jarisch","year":"2022","unstructured":"Jarisch A, Wiercinska E, Huenecke S, Bremm M, Cappel C, Hauler J, Rettinger E, Soerensen J, Hellstern H, Klusmann JH, Ciesek S, Bonig H, Bader P (2022) Immune responses to SARS-CoV-2 vaccination in young patients with anti-CD19 chimeric antigen receptor T cell-induced B cell aplasia. Transplant Cell Ther 28(7):366e1\u2013366e7. https:\/\/doi.org\/10.1016\/j.jtct.2022.04.017","journal-title":"Transplant Cell Ther"},{"key":"9116_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/tcrm.S22599","volume":"8","author":"P Wood","year":"2012","unstructured":"Wood P (2012) Human normal Immunoglobulin in the treatment of primary immunodeficiency diseases. Ther Clin Risk Manag 8:157\u2013167. https:\/\/doi.org\/10.2147\/tcrm.S22599","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"9116_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","volume":"27","author":"VS Negi","year":"2007","unstructured":"Negi VS, Elluru S, Sib\u00e9ril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27(3):233\u2013245. https:\/\/doi.org\/10.1007\/s10875-007-9088-9","journal-title":"J Clin Immunol"},{"issue":"1","key":"9116_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM (2010) Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 137(1):21\u201330. https:\/\/doi.org\/10.1016\/j.clim.2010.06.012","journal-title":"Clin Immunol"},{"issue":"2","key":"9116_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020024","volume":"9","author":"I Mahmood","year":"2020","unstructured":"Mahmood I, Tegenge MA, Golding B (2020) Considerations for optimizing dosing of immunoglobulins based on pharmacokinetic evidence. Antibodies (Basel) 9(2):24. https:\/\/doi.org\/10.3390\/antib9020024","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"9116_CR82","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","volume":"161","author":"RL Wasserman","year":"2010","unstructured":"Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, Chen J, Sorrells S, Roberts R, Gupta S (2010) Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 161(3):518\u2013526. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04195.x","journal-title":"Clin Exp Immunol"},{"key":"9116_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z (2018) Adverse effects of immunoglobulin therapy. Front Immunol 9:1299. https:\/\/doi.org\/10.3389\/fimmu.2018.01299","journal-title":"Front Immunol"},{"issue":"2","key":"9116_CR84","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","volume":"127","author":"EM Ammann","year":"2016","unstructured":"Ammann EM, Jones MP, Link BK, Carnahan RM, Winiecki SK, Torner JC, McDowell BD, Fireman BH, Chrischilles EA (2016) Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127(2):200\u2013207. https:\/\/doi.org\/10.1182\/blood-2015-05-647552","journal-title":"Blood"},{"key":"9116_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2015.12.001","volume":"361","author":"Y Nakano","year":"2016","unstructured":"Nakano Y, Hayashi T, Deguchi K, Sato K, Hishikawa N, Yamashita T, Ohta Y, Takao Y, Morio T, Abe K (2016) Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy. J Neurol Sci 361:9\u201312. https:\/\/doi.org\/10.1016\/j.jns.2015.12.001","journal-title":"J Neurol Sci"},{"key":"9116_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","volume":"6","author":"PJ Sp\u00e4th","year":"2015","unstructured":"Sp\u00e4th PJ, Granata G, La Marra F, Kuijpers TW, Quinti I (2015) On the dark side of therapies with Immunoglobulin concentrates: the adverse events. Front Immunol 6:11. https:\/\/doi.org\/10.3389\/fimmu.2015.00011","journal-title":"Front Immunol"},{"issue":"3","key":"9116_CR87","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10875-016-0243-z","volume":"36","author":"MA Rojavin","year":"2016","unstructured":"Rojavin MA, Hubsch A, Lawo JP (2016) Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency. J Clin Immunol 36(3):210\u2013219. https:\/\/doi.org\/10.1007\/s10875-016-0243-z","journal-title":"J Clin Immunol"},{"issue":"1","key":"9116_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","volume":"122","author":"VR Bonagura","year":"2008","unstructured":"Bonagura VR, Marchlewski R, Cox A, Rosenthal DW (2008) Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 122(1):210\u2013212. https:\/\/doi.org\/10.1016\/j.jaci.2008.04.044","journal-title":"J Allergy Clin Immunol"},{"key":"9116_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-015-0092-y","volume":"11","author":"F Jiang","year":"2015","unstructured":"Jiang F, Torgerson TR, Ayars AG (2015) Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol 11:27. https:\/\/doi.org\/10.1186\/s13223-015-0092-y","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"9116_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00726-7","volume":"18","author":"K Epland","year":"2022","unstructured":"Epland K, Suez D, Paris K (2022) A clinician\u2019s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol 18(1):87. https:\/\/doi.org\/10.1186\/s13223-022-00726-7","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"9116_CR91","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10875-021-00990-z","volume":"41","author":"Z Li","year":"2021","unstructured":"Li Z, McCoy B, Engl W, Yel L (2021) Steady-state serum IgG trough levels are adequate for pharmacokinetic assessment in patients with immunodeficiencies receiving subcutaneous immune globulin. J Clin Immunol 41(6):1331\u20131338. https:\/\/doi.org\/10.1007\/s10875-021-00990-z","journal-title":"J Clin Immunol"},{"issue":"10","key":"9116_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100068","volume":"12","author":"P Shrestha","year":"2019","unstructured":"Shrestha P, Karmacharya P, Wang Z, Donato A, Joshi AY (2019) Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: a systematic review and meta-analysis of clinical studies. World Allergy Organ J 12(10):100068. https:\/\/doi.org\/10.1016\/j.waojou.2019.100068","journal-title":"World Allergy Organ J"},{"issue":"1","key":"9116_CR93","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/curroncol30010022","volume":"30","author":"A Visentin","year":"2022","unstructured":"Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, Ruocco V, Imbergamo S, Piazza F, Proietti G, Mauro FR, Trentin L (2022) A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency. Curr Oncol 30(1):274\u2013283. https:\/\/doi.org\/10.3390\/curroncol30010022","journal-title":"Curr Oncol"},{"issue":"Suppl 1","key":"9116_CR94","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cei.12555","volume":"178","author":"S Jolles","year":"2014","unstructured":"Jolles S, Jordan SC, Orange JS, van Schaik IN (2014) Immunoglobulins: current Understanding and future directions. Clin Exp Immunol 178(Suppl 1):163\u2013168. https:\/\/doi.org\/10.1111\/cei.12555","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"9116_CR95","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1586\/1744666x.2014.957678","volume":"10","author":"RL Wasserman","year":"2014","unstructured":"Wasserman RL (2014) Hizentra for the treatment of primary immunodeficiency. Expert Rev Clin Immunol 10(10):1293\u20131307. https:\/\/doi.org\/10.1586\/1744666x.2014.957678","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"9116_CR96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.15761\/ccrr.1000149","volume":"1","author":"SN Shah","year":"2015","unstructured":"Shah SN, Todoric K, Tarrant TK (2015) Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease. Clin Case Rep Rev 1(7):151\u2013152. https:\/\/doi.org\/10.15761\/ccrr.1000149","journal-title":"Clin Case Rep Rev"},{"issue":"6","key":"9116_CR97","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","volume":"50","author":"RL Wasserman","year":"2011","unstructured":"Wasserman RL, Melamed I, Nelson RP Jr., Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA (2011) Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 50(6):405\u2013414. https:\/\/doi.org\/10.2165\/11587030-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"15 Suppl","key":"9116_CR98","first-page":"s475","volume":"22","author":"G Krishnarajah","year":"2016","unstructured":"Krishnarajah G, Lehmann JK, Ellman B, Bhak RH, DerSarkissian M, Leader D Jr., Bullinger AL, Sheng Duh M (2016) Evaluating dose ratio of subcutaneous to intravenous Immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous Immunoglobulin therapy. Am J Manag Care 22(15 Suppl):s475\u2013s481","journal-title":"Am J Manag Care"},{"issue":"1","key":"9116_CR99","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","volume":"141","author":"S Jolles","year":"2011","unstructured":"Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-H\u00fcber J, Zenker O, Grimbacher B (2011) Efficacy and safety of Hizentra(\u00ae) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 141(1):90\u2013102. https:\/\/doi.org\/10.1016\/j.clim.2011.06.002","journal-title":"Clin Immunol"},{"issue":"2","key":"9116_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.anpedi.2008.11.011","volume":"70","author":"M Maroto Hernando","year":"2009","unstructured":"Maroto Hernando M, Soler Palac\u00edn P, Martin Nalda N, Oliveras Arenas M, Espa\u00f1ol Boren T, Figueras Nadal C (2009) Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain. Pediatr (Barc) 70(2):111\u2013119 Gammaglobulina subcut\u00e1nea en inmunodeficiencia com\u00fan variable. Primera experiencia en Espa\u00f1a. https:\/\/doi.org\/10.1016\/j.anpedi.2008.11.011","journal-title":"Pediatr (Barc)"},{"issue":"4","key":"9116_CR101","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10875-010-9417-2","volume":"30","author":"S Th\u00e9pot","year":"2010","unstructured":"Th\u00e9pot S, Malphettes M, Gardeur A, Galicier L, Asli B, Karlin L, G\u00e9rard L, Laumont R, Doize ML, Arnulf B, Fieschi C, Bengoufa D, Oksenhendler E (2010) Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 30(4):602\u2013606. https:\/\/doi.org\/10.1007\/s10875-010-9417-2","journal-title":"J Clin Immunol"},{"issue":"1","key":"9116_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-020-00371-y","volume":"21","author":"R Mallick","year":"2020","unstructured":"Mallick R, Henderson T, Lahue BJ, Kafal A, Bassett P, Scalchunes C (2020) Subcutaneous immunoglobulin in primary immunodeficiency - impact of training and infusion characteristics on patient-reported outcomes. BMC Immunol 21(1):47. https:\/\/doi.org\/10.1186\/s12865-020-00371-y","journal-title":"BMC Immunol"},{"issue":"8","key":"9116_CR103","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s10875-018-0562-3","volume":"38","author":"R Mallick","year":"2018","unstructured":"Mallick R, Jolles S, Kanegane H, Agbor-Tarh D, Rojavin M (2018) Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six Hizentra\u00ae studies. J Clin Immunol 38(8):886\u2013897. https:\/\/doi.org\/10.1007\/s10875-018-0562-3","journal-title":"J Clin Immunol"},{"issue":"1","key":"9116_CR104","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","volume":"31","author":"TM Windegger","year":"2017","unstructured":"Windegger TM, Lambooy CA, Hollis L, Morwood K, Weston H, Fung YL (2017) Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy. Transfus Med Rev 31(1):45\u201350. https:\/\/doi.org\/10.1016\/j.tmrv.2016.06.006","journal-title":"Transfus Med Rev"},{"key":"9116_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.05.059","author":"NC Patel","year":"2025","unstructured":"Patel NC, Walter JE (2025) Facilitated subcutaneous immunoglobulin 10% safety among pediatric patients with primary immunodeficiency diseases. The Journal of Allergy and Clinical Immunology: In Practice. https:\/\/doi.org\/10.1016\/j.jaip.2025.05.059","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"9116_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00981","volume":"11","author":"E Wiesik-Szewczyk","year":"2020","unstructured":"Wiesik-Szewczyk E, So\u0142dacki D, Paczek L, Jahnz-R\u00f3\u017cyk K (2020) Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: a two Center, Long-Term retrospective observation in adults with primary immunodeficiencies. Front Immunol 11:981. https:\/\/doi.org\/10.3389\/fimmu.2020.00981","journal-title":"Front Immunol"},{"issue":"4","key":"9116_CR107","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI (2012) Recombinant human hyaluronidase-facilitated subcutaneous infusion of human Immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 130(4):951\u20137e11. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.021","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"9116_CR108","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01771-0","volume":"44","author":"E Yalcin Gungoren","year":"2024","unstructured":"Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, Can S, Karabiber E, Yakici N, Orhan F, Cokugras H, Aydogan M, Ozdemir O, Bilgic Eltan S, Baris S, Ozen A, Karakoc-Aydiner E (2024) Insights into patient experiences with facilitated subcutaneous immunoglobulin therapy in primary immune deficiency: a prospective observational cohort. J Clin Immunol 44(8):169. https:\/\/doi.org\/10.1007\/s10875-024-01771-0","journal-title":"J Clin Immunol"},{"key":"9116_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670547","volume":"12","author":"NB Hustad","year":"2021","unstructured":"Hustad NB, Degerud HM, Hjelmerud I, Fraz MSA, Nord\u00f8y I, Tr\u00f8seid M, Fevang B, Aukrust P, J\u00f8rgensen SF (2021) Real-world experiences with facilitated subcutaneous immunoglobulin substitution in patients with hypogammaglobulinemia, using a three-step ramp-up schedule. Front Immunol 12:670547. https:\/\/doi.org\/10.3389\/fimmu.2021.670547","journal-title":"Front Immunol"},{"key":"9116_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184524","author":"M Dimou","year":"2023","unstructured":"Dimou M, Speletas M, Milito C, Pyzik A, Huscher D, Kamieniak M, Pittrow D, Borte M (2023) Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: a FIGARO subgroup analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15184524","journal-title":"Cancers (Basel)"},{"issue":"7","key":"9116_CR111","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.21873\/anticanres.12712","volume":"38","author":"M Dimou","year":"2018","unstructured":"Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P (2018) Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A single-center retrospective analysis. Anticancer Res 38(7):4187\u20134191. https:\/\/doi.org\/10.21873\/anticanres.12712","journal-title":"Anticancer Res"},{"issue":"3","key":"9116_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247717","volume":"16","author":"F Cinetto","year":"2021","unstructured":"Cinetto F, Neri R, Vianello F, Visentin A, Baril\u00e0 G, Gianese S, Lanciarotta A, Milito C, Rattazzi M, Piazza F, Trentin L, Zambello R, Agostini C, Scarpa R (2021) Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: real life evidence as compared to primary antibody deficiencies. PLoS One 16(3):e0247717. https:\/\/doi.org\/10.1371\/journal.pone.0247717","journal-title":"PLoS One"},{"issue":"6","key":"9116_CR113","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/2047-783x-15-6-238","volume":"15","author":"F Hoffmann","year":"2010","unstructured":"Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH (2010) Home-based subcutaneous Immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 15(6):238\u2013245. https:\/\/doi.org\/10.1186\/2047-783x-15-6-238","journal-title":"Eur J Med Res"},{"issue":"1","key":"9116_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00746-3","volume":"18","author":"R Mallick","year":"2022","unstructured":"Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O (2022) Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes. Allergy Asthma Clin Immunol 18(1):110. https:\/\/doi.org\/10.1186\/s13223-022-00746-3","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"9116_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294408","volume":"18","author":"A Abadeh","year":"2023","unstructured":"Abadeh A, Shehadeh S, Betschel S, Waserman S, Cameron DW, Cowan J (2023) Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: data from the Ontario immunoglobulin treatment case registry. PLoS One 18(11):e0294408. https:\/\/doi.org\/10.1371\/journal.pone.0294408","journal-title":"PLoS One"},{"issue":"1","key":"9116_CR116","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13223-014-0063-8","volume":"11","author":"AP Koterba","year":"2015","unstructured":"Koterba AP, Stein MR (2015) Initiation of Immunoglobulin therapy by subcutaneous administration in immunodeficiency patients Naive to replacement therapy. Allergy Asthma Clin Immunol 11(1):63. https:\/\/doi.org\/10.1186\/s13223-014-0063-8","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"9116_CR117","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","volume":"99","author":"N Compagno","year":"2014","unstructured":"Compagno N, Cinetto F, Semenzato G, Agostini C (2014) Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica 99(6):1101\u20131106. https:\/\/doi.org\/10.3324\/haematol.2013.101261","journal-title":"Haematologica"},{"issue":"3","key":"9116_CR118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/hon.2966","volume":"40","author":"I Innocenti","year":"2022","unstructured":"Innocenti I, Tomasso A, Benintende G, Autore F, Fresa A, Vuono F, Stirparo L, Galli E, D\u2019Arena G, Sor\u00e0 F, Efremov D, Laurenti L (2022) Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. Hematol Oncol 40(3):469\u2013474. https:\/\/doi.org\/10.1002\/hon.2966","journal-title":"Hematol Oncol"},{"issue":"8946","key":"9116_CR119","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0140-6736(95)90367-4","volume":"345","author":"L Hammarstr\u00f6m","year":"1995","unstructured":"Hammarstr\u00f6m L, Samuelsson J, Grimfors G (1995) Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia. Lancet 345(8946):382\u2013383","journal-title":"Lancet"},{"issue":"6","key":"9116_CR120","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/ajco.13515","volume":"17","author":"TM Windegger","year":"2021","unstructured":"Windegger TM, English J, Weston H, Morwood K, Kynn M, Scuffham P, Fung YL (2021) Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy. Asia Pac J Clin Oncol 17(6):546\u2013554. https:\/\/doi.org\/10.1111\/ajco.13515","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"9116_CR121","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.hemonc.2021.01.001","volume":"14","author":"I Pasic","year":"2021","unstructured":"Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, Kim DDH, Lipton JH, Michelis FV (2021) Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use. Hematol Oncol Stem Cell Ther 14(4):302\u2013310. https:\/\/doi.org\/10.1016\/j.hemonc.2021.01.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"9116_CR122","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","volume":"15","author":"T Shankar","year":"2013","unstructured":"Shankar T, Gribowicz J, Crespo M, Silveira FP, Pilewski J, Petrov AA (2013) Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients. Int Immunopharmacol 15(4):752\u2013755. https:\/\/doi.org\/10.1016\/j.intimp.2013.02.021","journal-title":"Int Immunopharmacol"},{"key":"9116_CR123","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57:24\u201329. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.004","journal-title":"J Autoimmun"},{"key":"9116_CR124","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","volume":"166","author":"G Spadaro","year":"2016","unstructured":"Spadaro G, Pecoraro A, De Renzo A, Della Pepa R, Genovese A (2016) Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol 166:103\u2013104. https:\/\/doi.org\/10.1016\/j.clim.2016.04.001","journal-title":"Clin Immunol"},{"issue":"1\u20132","key":"9116_CR125","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","volume":"4","author":"J Sidhu","year":"2014","unstructured":"Sidhu J, Rojavin M, Pfister M, Edelman J (2014) Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency. Biol Ther 4(1\u20132):41\u201355. https:\/\/doi.org\/10.1007\/s13554-014-0018-0","journal-title":"Biol Ther"},{"key":"9116_CR126","unstructured":"U.S. Food and Drug Administration (2021) Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid, Hizentra\u00ae Full Prescribing Information. Accessed Sep 23, 2025. https:\/\/www.fda.gov\/media\/78466\/download"},{"issue":"2","key":"9116_CR127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","volume":"179","author":"S Jolles","year":"2015","unstructured":"Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, Berger M (2015) Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 179(2):146\u2013160. https:\/\/doi.org\/10.1111\/cei.12485","journal-title":"Clin Exp Immunol"},{"key":"9116_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00040","volume":"10","author":"RH Kobayashi","year":"2019","unstructured":"Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J (2019) Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig\u00ae]) in the treatment of patients with primary immunodeficiencies. Front Immunol 10:40. https:\/\/doi.org\/10.3389\/fimmu.2019.00040","journal-title":"Front Immunol"},{"issue":"3","key":"9116_CR129","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10198-021-01378-x","volume":"23","author":"L Alsina","year":"2022","unstructured":"Alsina L, Montoro JB, Moral PM, Neth O, Pica MO, S\u00e1nchez-Ram\u00f3n S, Presa M, Oyag\u00fcez I, Casado M, Gonz\u00e1lez-Granado LI (2022) Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. Eur J Health Econ 23(3):551\u2013558. https:\/\/doi.org\/10.1007\/s10198-021-01378-x","journal-title":"Eur J Health Econ"},{"issue":"2","key":"9116_CR130","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","volume":"120","author":"LW Fu","year":"2018","unstructured":"Fu LW, Song C, Isaranuwatchai W, Betschel S (2018) Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis. Ann Allergy Asthma Immunol 120(2):195\u2013199. https:\/\/doi.org\/10.1016\/j.anai.2017.11.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9116_CR131","doi-asserted-by":"publisher","DOI":"10.14196\/mjiri.31.94","volume":"31","author":"H Shabaninejad","year":"2017","unstructured":"Shabaninejad H, Asgharzadeh A, Rezapour A, Rezaei N (2017) Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies. Med J Islam Repub Iran 31:94. https:\/\/doi.org\/10.14196\/mjiri.31.94","journal-title":"Med J Islam Repub Iran"},{"issue":"2","key":"9116_CR132","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2450\/2029.0083-19","volume":"18","author":"TM Windegger","year":"2020","unstructured":"Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA (2020) Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous Immunoglobulin replacement therapy in Australia. Blood Transfus 18(2):96\u2013105. https:\/\/doi.org\/10.2450\/2029.0083-19","journal-title":"Blood Transfus"},{"issue":"3","key":"9116_CR133","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/vox.12760","volume":"114","author":"TM Windegger","year":"2019","unstructured":"Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA (2019) Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang 114(3):237\u2013246. https:\/\/doi.org\/10.1111\/vox.12760","journal-title":"Vox Sang"},{"issue":"1","key":"9116_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-23","volume":"10","author":"WC Gerth","year":"2014","unstructured":"Gerth WC, Betschel SD, Zbrozek AS (2014) Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Allergy Asthma Clin Immunol 10(1):23. https:\/\/doi.org\/10.1186\/1710-1492-10-23","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09116-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T10:53:45Z","timestamp":1765018425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09116-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9116"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09116-4","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"106"}}